Literature DB >> 18512118

Terminal deoxynucleotidyl transferase negative T-cell lymphoblastic lymphoma in aleukemic patient.

Iva Brčić1, Boris Labar2, Melita Perić-Balja1, Sandra Bašić-Kinda2, Marin Nola3.   

Abstract

Precursor lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is a malignant neoplasm of precursor lymphocytes of T- or B-cell phenotype. We describe the unusual features of an ALL/LBL in an adolescent man in whom the disease presented with involvement of lymph nodes, but without bone marrow and peripheral blood involvement. Immunohistochemical studies revealed that the tumor cells were positive for CD3, CD34 class II, CD10, CD79a and CD99 but negative for TdT. Even though TdT was negative, he received ALL-therapy and is now in remission.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18512118     DOI： 10.1007/s12185-008-0101-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  7 in total

1.  Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Authors:  A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections: a useful method for the diagnosis of lymphoblastic lymphoma.

Authors:  J Suzumiya; K Ohshima; M Kikuchi; M Takeshita; M Akamatsu; K Tashiro
Journal:  J Pathol       Date:  1997-05       Impact factor: 7.996

3.  MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities.

Authors:  R A Soslow; V Bhargava; R A Warnke
Journal:  Hum Pathol       Date:  1997-10       Impact factor: 3.466

4.  The immunophenotype of pre-TALL/LBL revisited.

Authors:  Robert E Lewis; Julius M Cruse; Catherine M Sanders; Rachel N Webb; Benjamin F Tillman; Kevin L Beason; John Lam; Jonathan Koehler
Journal:  Exp Mol Pathol       Date:  2006-08-14       Impact factor: 3.362

5.  Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia.

Authors:  J Faber; H Kantarjian; M W Roberts; M Keating; E Freireich; M Albitar
Journal:  Arch Pathol Lab Med       Date:  2000-01       Impact factor: 5.534

6.  Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.

Authors:  Dieter Hoelzer; Nicola Gökbuget; Werner Digel; Thomas Faak; Michael Kneba; Regina Reutzel; Joanna Romejko-Jarosinska; Jacek Zwolinski; Jan Walewski
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

7.  Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.

Authors:  Zahid Kaleem; Eric Crawford; M Hanif Pathan; Leah Jasper; Michael A Covinsky; Lawrence R Johnson; Glenda White
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534
  7 in total
  1 in total

1.  Terminal deoxynucleotidyl transferase (TdT)-negative T-cell lymphoblastic lymphoma with loss of the T-cell lineage-specific marker CD3 at relapse: a rare entity with an aggressive outcome.

Authors:  Masroor Hassan; Hafez Mohammad Ammar Abdullah; Abdul Wahid; Muhammad Ashraf Qamar
Journal:  BMJ Case Rep       Date:  2018-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.